Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition
Many Approved Prolia/Xgeva Rivals Await Launch In US And Europe
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
